Physician profile
Amy B Johnson
NPI 1407082118
$808.37
in general payments reported to CMS, 2019-2025
12 companies · $62.43 in 2025
The $62.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $251 · 2021: $49.32 · 2022: $222 · 2023: $14.67 · 2025: $62.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $222.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $149.33 | 2019-2022 | |
| Amgen INC. | $96.22 | 2019-2025 | Evenity |
| Astrazeneca Pharmaceuticals Lp | $89.69 | 2019-2022 | |
| Pfizer INC. | $74.79 | 2019-2025 | |
| Lilly USA, LLC | $68.92 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.39 | 2020-2021 | |
| Abbott Laboratories | $20.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.67 | 2023 | Quviviq |
| Abbvie INC. | $13.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.